Lincoln Pharmaceuticals has been awarded a patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray) by the Government of India. The patent is valid for 20 years. The company has necessary approvals from the Drug Controller General of India and is planning to launch it in the Indian market by January 2020.
The company is also planning to apply for a global patent for this ‘novel’ solution. Shares of Lincoln Pharmaceuticals jumped 4.24 per cent at ₹159.70 on the NSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.